BLCO
Bausch + Lomb Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+26/100
Last price
17.18
▲ 0.01 (0.06%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
17.17
Day high
17.31
Day low
16.95
Volume
319.70K
Market cap
$6.14B
P/E (TTM)
—
52W range
13.77 – 18.92
Trailing performance
Returnvs SPY
1W
+0.23%
-1.7%
1M
-4.77%
-5.9%
3M
+3.12%
-1.4%
6M
+7.91%
-10.3%
YTD
+0.59%
-13.7%
1Y
+13.03%
-3.4%
3Y
+1.36%
-80.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BLCO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+931.79K
Net buying
Buy transactions
32
1.00M shares
Sell transactions
2
71.46K shares
Net transactions
+34
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
311.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 500 | $8.37K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 541 | $9.06K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 4.77K | $79.83K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 6.52K | $109.28K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 1.50K | $25.15K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 11.10K | $186.16K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 200 | $3.35K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 3.00K | $50.33K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 2.34K | $39.33K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 700 | $11.75K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 2.21K | $37.09K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 4.61K | $77.40K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 7.54K | $126.73K | Direct |
| Aug 10, 26 | Munsch (Frederick John) Senior Officer of Issuer |
SELL | 4.44K | $74.66K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Appio (Thomas J) |
Director or Senior Officer of 10% Security Holder | 27.58K | Exercise of rights |
Bailey (Ambrose Robert Douglas J.D.) |
Senior Officer of Issuer | 141.11K | Exercise of rights |
Bausch Health Companies Inc. |
10% Security Holder of Issuer | — | Change in nature of ownership |
Bonnefoy (Luc) |
Senior Officer of Issuer | 35.44K | Exercise of rights |
Eldessouky (Osama A) |
Senior Officer of Issuer | 201.00K | Exercise of rights |
Hashad (Yehia) |
Senior Officer of Issuer | 107.52K | Exercise of rights |
Ling (Karen) |
Director of Issuer | 41.68K | Exercise of rights |
Munsch (Frederick John) |
Senior Officer of Issuer | 52.44K | Acquisition or disposition in the public market |
Saunders (Brent L.) |
Director of Issuer | 432.19K | Exercise of rights |
Stewart (Andrew Jude) |
Senior Officer of Issuer | 36.73K | Exercise of rights |
Fundamentals
Market cap$6.14B
Enterprise value$10.95B
Revenue (TTM)$5.32B
Gross profit$3.27B
EBITDA$816.00M
Net income$-171.00M
EPS (TTM)$-0.49
Free cash flow$323.00M
Total cash$367.00M
Total debt$5.11B
Book value / share$18.09
Shares outstanding357.17M
Float45.55M
Short % of float6.94%
Dividend yield0.00%
Beta (5Y)0.56
Valuation & profitability ratios
Trailing P/E—
Forward P/E15.44
PEG ratio0.89
Price / sales—
Price / book0.95
EV / revenue2.06
EV / EBITDA13.42
Gross margin61.44%
Operating margin7.75%
Profit margin-3.21%
Return on equity-2.52%
Return on assets1.83%
Debt / equity79.38
Current ratio1.55
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $5.10B | $4.79B | $4.15B | $3.77B | +6.5% |
| Operating revenue | $8.39B | $7.49B | $4.13B | $3.75B | +12.0% |
| Cost of revenue | $2.05B | $1.87B | $1.64B | $1.52B | +9.5% |
| Gross profit | $3.05B | $2.92B | $2.50B | $2.25B | +4.5% |
| Research & development | $371.00M | $343.00M | $324.00M | $307.00M | +8.2% |
| Selling, general & admin | $2.23B | $2.08B | $1.74B | $1.48B | +7.3% |
| Total operating expense | $2.86B | $2.71B | $2.30B | $2.03B | +5.5% |
| Operating income | $188.00M | $206.00M | $204.00M | $220.00M | -8.7% |
| Net interest income | -$409.00M | -$384.00M | -$268.00M | -$140.00M | -6.5% |
| Pre-tax income | -$317.00M | -$234.00M | -$166.00M | $73.00M | -35.5% |
| Tax provision | $35.00M | $71.00M | $82.00M | $58.00M | -50.7% |
| Net income | -$360.00M | -$317.00M | -$260.00M | $6.00M | -13.6% |
| Net income to common | -$360.00M | -$317.00M | -$260.00M | $6.00M | -13.6% |
| Basic EPS | -1.02 | -0.90 | -0.74 | 0.02 | -13.3% |
| Diluted EPS | -1.02 | -0.90 | -0.74 | 0.02 | -13.3% |
| EBIT | $104.00M | $165.00M | $117.00M | $219.00M | -37.0% |
| EBITDA | $525.00M | $601.00M | $499.00M | $598.00M | -12.6% |
| Basic shares | 353.80M | 351.80M | 350.50M | 350.00M | +0.6% |
| Diluted shares | 353.80M | 351.80M | 350.50M | 350.00M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $383.00M | $305.00M | $331.00M | $354.00M | +25.6% |
| Cash & short-term investments | $383.00M | $305.00M | $331.00M | $354.00M | +25.6% |
| Accounts receivable | $1.22B | $1.03B | $839.00M | $724.00M | +19.0% |
| Inventory | $976.00M | $1.04B | $1.03B | $628.00M | -5.8% |
| Total current assets | $2.98B | $2.79B | $2.74B | $2.14B | +6.8% |
| Property, plant & equipment | $1.76B | $1.49B | $1.39B | $1.30B | +18.7% |
| Goodwill & intangibles | $8.04B | $8.02B | $8.16B | $6.57B | +0.3% |
| Total assets | $14.02B | $13.47B | $13.44B | $11.14B | +4.1% |
| Total current liabilities | $1.92B | $1.74B | $1.58B | $1.30B | +10.5% |
| Current debt | $39.00M | $40.00M | $30.00M | $25.00M | -2.5% |
| Long-term debt | $5.04B | $4.74B | $4.53B | $2.41B | +6.3% |
| Total debt | $5.08B | $4.78B | $4.56B | $2.44B | +6.2% |
| Total liabilities | $7.50B | $6.92B | $6.52B | $4.04B | +8.3% |
| Retained earnings | -$931.00M | -$571.00M | -$254.00M | $6.00M | -63.0% |
| Shareholder equity | $6.45B | $6.47B | $6.85B | $7.03B | -0.4% |
| Working capital | $1.06B | $1.05B | $1.16B | $841.00M | +0.7% |
| Net tangible assets | -$1.59B | -$1.54B | -$1.31B | $468.00M | -3.0% |
| Shares issued | 354.21M | 352.40M | 350.91M | 350.00M | +0.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$352.00M | -$305.00M | -$248.00M | $15.00M | -15.4% |
| Depreciation & amortisation | $421.00M | $436.00M | $382.00M | $379.00M | -3.4% |
| Stock-based compensation | $149.00M | $92.00M | $74.00M | $62.00M | +62.0% |
| Change in working capital | $18.00M | -$87.00M | -$287.00M | -$19.00M | +120.7% |
| Operating cash flow | $283.00M | $232.00M | -$17.00M | $345.00M | +22.0% |
| Capital expenditure | -$349.00M | -$291.00M | -$181.00M | -$175.00M | -19.9% |
| Investing cash flow | -$455.00M | -$412.00M | -$2.11B | -$215.00M | -10.4% |
| Financing cash flow | $225.00M | $178.00M | $2.08B | $81.00M | +26.4% |
| Free cash flow | -$66.00M | -$59.00M | -$198.00M | $170.00M | -11.9% |
| End cash position | $397.00M | $316.00M | $334.00M | $380.00M | +25.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.39B | $1.24B | $1.41B | $1.28B | $1.28B | +12.1% |
| Operating revenue | $1.39B | $1.24B | $4.71B | $1.28B | $1.27B | +12.1% |
| Cost of revenue | $527.00M | $483.00M | $533.00M | $510.00M | $525.00M | +9.1% |
| Gross profit | $867.00M | $761.00M | $872.00M | $771.00M | $753.00M | +13.9% |
| Research & development | $114.00M | $101.00M | $94.00M | $95.00M | $96.00M | +12.9% |
| Selling, general & admin | $588.00M | $544.00M | $564.00M | $528.00M | $579.00M | +8.1% |
| Total operating expense | $759.00M | $702.00M | $714.00M | $691.00M | $742.00M | +8.1% |
| Operating income | $108.00M | $59.00M | $158.00M | $80.00M | $11.00M | +83.1% |
| Net interest income | -$89.00M | -$93.00M | -$95.00M | -$98.00M | -$125.00M | +4.3% |
| Pre-tax income | -$11.00M | -$64.00M | $13.00M | -$3.00M | -$147.00M | +82.8% |
| Tax provision | -$1.00M | $6.00M | $71.00M | $22.00M | -$89.00M | -116.7% |
| Net income | -$14.00M | -$71.00M | -$58.00M | -$28.00M | -$62.00M | +80.3% |
| Net income to common | -$14.00M | -$71.00M | -$58.00M | -$28.00M | -$62.00M | +80.3% |
| Basic EPS | -0.04 | -0.20 | -0.16 | -0.08 | -0.18 | +80.0% |
| Diluted EPS | -0.04 | -0.20 | -0.16 | -0.08 | -0.18 | +80.0% |
| EBIT | $82.00M | $33.00M | $111.00M | $98.00M | -$19.00M | +148.5% |
| EBITDA | $184.00M | $134.00M | $210.00M | $207.00M | $88.00M | +37.3% |
| Basic shares | 357.10M | 355.20M | 354.40M | 354.20M | 353.70M | +0.5% |
| Diluted shares | 357.10M | 355.20M | 354.40M | 354.20M | 353.70M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $367.00M | $268.00M | $383.00M | $310.00M | $266.00M | +36.9% |
| Cash & short-term investments | $367.00M | $268.00M | $383.00M | $310.00M | $266.00M | +36.9% |
| Accounts receivable | $1.16B | $1.11B | $1.22B | $1.09B | $1.08B | +4.9% |
| Inventory | $999.00M | $977.00M | $976.00M | $1.00B | $1.05B | +2.3% |
| Total current assets | $2.92B | $2.78B | $2.98B | $2.85B | $2.85B | +5.3% |
| Property, plant & equipment | $1.80B | $1.79B | $1.76B | $1.71B | $1.68B | +0.3% |
| Goodwill & intangibles | $7.89B | $7.96B | $8.04B | $7.99B | $8.03B | -0.9% |
| Total assets | $13.86B | $13.78B | $14.02B | $13.83B | $13.83B | +0.6% |
| Total current liabilities | $1.89B | $1.82B | $1.92B | $1.90B | $1.84B | +3.8% |
| Current debt | $43.00M | $39.00M | $39.00M | $28.00M | $28.00M | +10.3% |
| Long-term debt | $5.07B | $5.03B | $5.04B | $4.92B | $4.93B | +0.8% |
| Total debt | $5.12B | $5.07B | $5.08B | $4.95B | $4.96B | +0.9% |
| Total liabilities | $7.42B | $7.33B | $7.50B | $7.33B | $7.32B | +1.2% |
| Retained earnings | -$1.02B | -$1.00B | -$931.00M | -$873.00M | -$845.00M | -1.4% |
| Shareholder equity | $6.38B | $6.38B | $6.45B | $6.43B | $6.44B | -0.0% |
| Working capital | $1.03B | $956.00M | $1.06B | $959.00M | $1.01B | +7.9% |
| Net tangible assets | -$1.52B | -$1.58B | -$1.59B | -$1.56B | -$1.59B | +4.3% |
| Shares issued | 357.06M | 356.40M | 354.21M | 354.09M | 353.80M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.00M | -$70.00M | -$58.00M | -$25.00M | -$58.00M | +85.7% |
| Depreciation & amortisation | $102.00M | $101.00M | $99.00M | $109.00M | $107.00M | +1.0% |
| Stock-based compensation | $38.00M | $34.00M | $64.00M | $27.00M | $30.00M | +11.8% |
| Change in working capital | $19.00M | -$46.00M | -$67.00M | $37.00M | $48.00M | +141.3% |
| Operating cash flow | $153.00M | $32.00M | $136.00M | $137.00M | $35.00M | +378.1% |
| Capital expenditure | -$71.00M | -$100.00M | -$76.00M | -$74.00M | -$89.00M | +29.0% |
| Investing cash flow | -$87.00M | -$130.00M | -$188.00M | -$61.00M | -$90.00M | +33.1% |
| Financing cash flow | $34.00M | -$20.00M | $116.00M | -$12.00M | $90.00M | +270.0% |
| Free cash flow | $82.00M | -$68.00M | $60.00M | $63.00M | -$54.00M | +220.6% |
| End cash position | $378.00M | $279.00M | $397.00M | $332.00M | $272.00M | +35.5% |
Options analytics
Put / call volume
0.39
Call-heavy session
Put / call open interest
0.06
Positioning, not flow
Max pain
17.00
-1.0% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
109
Contracts, this expiry
Put volume
43
Contracts, this expiry
Heaviest call OI
20.00
2.00K contracts
Heaviest put OI
17.00
128 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.16 | 0.16 | -0.3% |
| Mar 2026 | 0.05 | 0.08 | +49.2% |
| Dec 2025 | 0.36 | 0.32 | -10.3% |
| Sep 2025 | 0.16 | 0.18 | +11.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.22 | 13 | $1.37B | +7.0% |
| Next quarter | 0.35 | 13 | $1.49B | +5.7% |
| Current year | 0.81 | 13 | $5.49B | +7.7% |
| Next year | 1.11 | 13 | $5.82B | +5.9% |
Analyst targets & ownership
Mean target$19.04
High target$24.00
Low target$16.00
Implied upside10.82%
Analyst count13
ConsensusBUY
Strong buy / Buy1 / 5
Hold7
Sell / Strong sell0 / 1
Held by insiders87.29%
Held by institutions11.14%
Institutions holding123
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
17.02
+0.94% from price
SMA 20
17.12
+0.35% from price
SMA 50
17.13
+0.32% from price
SMA 100
16.51
+4.08% from price
SMA 200
16.64
+3.24% from price
EMA 12
17.09
+0.52% from price
EMA 26
17.12
+0.34% from price
EMA 50
17.01
+0.98% from price
RSI (14)
51.4
Neutral
MACD (12,26,9)
-0.03
Hist 0.00
ATR (14)
0.40
2.32% of price
Realised vol 30D
20.1%
Annualised
Bollinger upper
17.66
20, 2σ
Bollinger lower
16.58
20, 2σ
50 / 200 cross
Golden
17.13 vs 16.64
Trend bias
Above 200
+3.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.96
Less volatile than market
Correlation to SPY
0.44
Loosely linked
Realised vol 30D
20.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-20.1%
Peak to trough
Max drawdown 5Y
-48.1%
Peak to trough
ATR 14
0.40
2.32% of price
Beta (reported)
0.56
5Y monthly, from filing
Short interest
Shares short
3.16M
Prior 3.18M
Change vs prior
-0.5%
Shorts covering
% of float
6.94%
Normal
% of shares out
0.89%
Against total outstanding
Days to cover
7.5
Crowded exit
Float
45.55M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 26 | Needham | MAINTAINED | Hold | Hold |
| Sep 9, 26 | Leerink Partners | INITIATED | — | Outperform |
| Aug 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 30, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 28, 26 | UBS | INITIATED | — | Buy |
| Jul 8, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Evercore ISI Group | MAINTAINED | In-Line | In-Line |
| Apr 30, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Apr 30, 26 | Evercore ISI Group | MAINTAINED | In-Line | In-Line |
| Apr 6, 26 | Evercore ISI Group | MAINTAINED | In-Line | In-Line |
| Feb 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K/A · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-08-06
Periodic Financial Reports
10-Q · 2026-07-29
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-06-01
Corporate Changes & Voting Matters
8-K · 2026-05-20
Corporate Changes & Voting Matters
8-K · 2026-04-29
Proxy Statements
DEF 14A · 2026-04-10
Corporate Changes & Voting Matters
8-K · 2026-02-18
Headlines
Bausch + Lomb Advances Oral Dry AMD Treatment Development
MT Newswires · 15h ago
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Business Wire · 15h ago
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
Business Wire · 2d ago
SpyGlass Pharma Acquires Advanced Vision Science for $13 Million
MT Newswires · 6d ago
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
GlobeNewswire · 6d ago
3 Small-Cap Stocks That Concern Us
StockStory · 20d ago
Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026
PR Newswire · 21d ago
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
Zacks · 23d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.